• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    715.04 +0.57 (+0.08%)
    Streaming Delayed Price Updated: 1:28 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
    It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
    Via Talk Markets
    Topics ETFs Stocks / Equities
    If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
    Via Benzinga
    Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
    JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
    Via Benzinga
    Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
    Via Benzinga
    Regeneron Pharmaceuticals Unusual Options Activity
    Via Benzinga
    Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
    Via Benzinga
    Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
    Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025. 
    Via Benzinga
    Exposures Product Safety
    Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
    Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Peering Into Regeneron Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Check Out What Whales Are Doing With REGN
    Via Benzinga
    28 Analysts Have This To Say About Regeneron Pharmaceuticals
    Via Benzinga
    EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
    The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
    Via Investor's Business Daily
    Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
    Via Benzinga
    Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
    Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges. 
    Via Benzinga
    It’s Been A Tough Month For Healthcare Stocks
    It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
    Via Talk Markets
    Topics ETFs Stocks / Equities
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    Not-So-Big Pharma
    Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
    Via Talk Markets
    FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
    Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
    Via Benzinga
    Exposures Product Safety
    Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 Top Growth Stocks to Buy on the Dip
    Their recent issues are nothing to fret over for investors focused on the long game. 
    Via The Motley Fool
    Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
    After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
    Via Benzinga
    Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Announces Investor Conference Presentations
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.